局限性与转移性膀胱癌的经济负担
本系统综述遵循PRISMA规范,检索PubMed/Medline、Embase及公共来源,评估膀胱癌在医疗与患者视角下的费用、成本效果与财务毒性。结果显示高危非肌层浸润性膀胱癌经卡介苗治疗后进展者5年费用超过20万美元,肌层浸润性膀胱癌根治性膀胱切除术手术费用平均3万至4万美元,转移性膀胱癌全身治疗每五周期疗程费用4万至超10万美元,财务毒性在年轻、受教育程度较低和少数族群中尤为普遍。
要点
- 高危非肌层浸润性膀胱癌经卡介苗治疗进展后5年费用超过20万美元。
- 肌层浸润性膀胱癌根治性膀胱切除术手术费用平均3万至4万美元,并发症增加额外费用。
- 转移性膀胱癌全身治疗每五周期疗程费用4万至超10万美元,联合治疗进一步增加。
核心结论
- 膀胱癌治疗尤其在晚期阶段造成显著经济负担,照护创新在改善肿瘤学结局的同时需详细的成本效果评估。
- 应对这些经济挑战对于优化膀胱癌管理、针对财务毒性高风险患者及改善生活质量至关重要。
研究设计与样本
- 遵循PRISMA规范的系统综述,检索PubMed/Medline、Embase及公共来源,纳入评估膀胱癌财务影响(费用、成本效果和财务毒性)的研究。
主要发现
- 高危非肌层浸润性膀胱癌经卡介苗治疗进展后5年费用超过20万美元,包括住院、门诊和医师服务费用。
- 肌层浸润性膀胱癌根治性膀胱切除术手术费用平均3万至4万美元,并发症时产生额外费用。
- 三联治疗1年管理成本超过20万美元,高于根治性膀胱切除术,因门诊、影像学和药物费用更高。
- 转移性膀胱癌全身治疗每五周期疗程费用4万至超10万美元,联合治疗(如恩诺单抗维多汀和帕博利珠单抗)、治疗相关毒性和支持治疗进一步增加费用。
- 财务毒性在年轻、受教育程度较低和少数族群中尤为普遍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of treatment cost effectiveness. Here, we aim to systematically review and analyze the financial burden of BCa from the health care and patient perspectives. METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-compliant systematic review was conducted, searching PubMed/Medline, Embase, and public sources for studies evaluating the financial impact of BCa, encompassing costs, cost effectiveness, and financial toxicity (FT). KEY FINDINGS AND LIMITATIONS: Non-muscle-invasive BCa (NMIBC) incurs significant costs for surveillance and treatment, with costs exceeding $200 000 after 5 yr for high-risk NMIBC patients progressing after bacillus Calmette-Guerin (BCG) treatment (including inpatient, outpatient, and physician service expenses). Muscle-invasive BCa generates substantial costs from radical cystectomy (RC) and neoadjuvant chemotherapy, averaging $30 000-40 000 from surgical costs of RC, with additional expenses in case of complications. Trimodal therapy has higher costs (1-yr management cost >$200 000) than RC because of higher outpatient, radiology, and medication costs. Metastatic BCa incurs the highest financial burden, with systemic therapy costs ranging from $40 000 to over $100 000 per five-cycle course, increasing further with combination therapies (ie, enfortumab vedotin and pembrolizumab), treatment-related toxicity, and supportive care. FT is particularly prevalent among younger, less educated, and minority populations. CONCLUSIONS AND CLINICAL IMPLICATIONS: BCa treatment, particularly in advanced stages, imposes a substantial economic burden. Innovations in care, while improving oncologic outcomes, necessitate detailed cost-effectiveness assessments. Addressing these economic challenges is essential for optimizing BCa management, targeting patients at a higher risk of FT, and improving patient quality of life.
引用
- Scilipoti P, Moschini M, Li R, et al. The Financial Burden of Localized and Metastatic Bladder Cancer. Eur Urol. 2024. PMID: 39730299. doi:10.1016/j.eururo.2024.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。